COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Chatzikonstantinou, Thomas
- dc.contributor.author Espinet Solà, Blanca
- dc.contributor.author Ghia, Paolo
- dc.date.accessioned 2022-06-28T06:19:38Z
- dc.date.available 2022-06-28T06:19:38Z
- dc.date.issued 2021
- dc.description.abstract Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41-0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02-1.04; HR = 1.79, 95% CI:1.04-3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.
- dc.format.mimetype application/pdf
- dc.identifier.citation Chatzikonstantinou T, Kapetanakis A, Scarfò L, Karakatsoulis G, Allsup D, Cabrero AA, et al. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia. 2021 Dec; 35(12): 3444-54. DOI: 10.1038/s41375-021-01450-8.
- dc.identifier.doi http://dx.doi.org/10.1038/s41375-021-01450-8
- dc.identifier.issn 0887-6924
- dc.identifier.uri http://hdl.handle.net/10230/53608
- dc.language.iso eng
- dc.publisher Nature Research
- dc.rights © The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.other COVID-19 (Malaltia)
- dc.subject.other Leucèmia
- dc.subject.other Mortalitat
- dc.title COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion